electroCore (NASDAQ: ECOR) has built a commercial-stage bioelectric medicine and wellness platform around non-invasive neuromodulation, with applications spanning prescription therapeutics, military human performance...
Closely held AINGENS is addressing one of healthcare’s most persistent operational challenges—the costly, laborious process of transforming scientific data into compliant, actionable content. The company developed an...
Alto Neuroscience (NYSE: ANRO) is aiming to redefine the way neuropsychiatric conditions are treated through a biology-driven pipeline designed to deliver more effective treatment options. Drawing on expertise in...
A pharmaceutical and life sciences technology, data, and consulting platform, IntegriChain delivers solutions that help companies manage the commercial and financial complexities of bringing therapies to market...
Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural...
Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...
OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...
The nonprofit organization Healing the Hero is bringing hope to U.S. military personnel, veterans, first responders, and Gold Star Families by leveraging neurolinguistic programming (NLP)-informed methods to directly...
Closely held Siloton is developing a patented miniaturized medical imaging platform that combines photonic chips with optical coherence tomography (OCT) to detect and monitor a range of prevalent ophthalmic diseases...
Closely held Pacylex Pharmaceuticals is developing a first-in-class oral cancer therapy with a novel, broad mechanism of action designed for refractory cancers as both a monotherapy and a future combination therapy.